{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:31:07Z","timestamp":1791361867214,"version":"4.3.1"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118436","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T14:45:10Z","timestamp":1788705910000},"page":"118436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites"],"prefix":"10.1016","volume":"254","author":[{"given":"Ailie","family":"Marx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maor","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ruthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2218-2039","authenticated-orcid":false,"given":"Jamal","family":"Mahajna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118436_b0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0022-2836(65)80285-6","article-title":"On the nature of allosteric transitions: a plausible model","volume":"12","author":"Monod","year":"1965","journal-title":"J. Mol. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118436_b0010","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase","volume":"112","author":"Nagar","year":"2003","journal-title":"Cell"},{"issue":"7280","key":"10.1016\/j.bcp.2026.118436_b0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"issue":"7647","key":"10.1016\/j.bcp.2026.118436_b0020","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118436_b0025","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.bcp.2026.118436_b0030","first-page":"0747","article-title":"Advancements in protein kinase inhibitors: from discovery to clinical applications","volume":"8","author":"Baldi","year":"2025","journal-title":"Research (Wash DC)"},{"issue":"19","key":"10.1016\/j.bcp.2026.118436_b0035","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1182\/blood.2024026052","article-title":"The promise of allosteric kinase inhibition","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2026.118436_b0040","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1021\/acs.jmedchem.0c02076","article-title":"Structure- and similarity-based survey of allosteric kinase inhibitors, activators, and closely related compounds","volume":"65","author":"Laufk\u00f6tter","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118436_b0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.118436_b0050","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s40262-024-01428-6","article-title":"Clinical pharmacology of asciminib: a review","volume":"63","author":"Hoch","year":"2024","journal-title":"Clin. Pharmacokinet."},{"issue":"14","key":"10.1016\/j.bcp.2026.118436_b0055","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118436_b0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2015.10.002","article-title":"Allosteric small-molecule kinase inhibitors","volume":"156","author":"Wu","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2026.118436_b0065","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1021\/acs.jmedchem.2c00073","article-title":"Principles of kinase allosteric inhibition and pocket validation","volume":"65","author":"Pan","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118436_b0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.drudis.2015.07.008","article-title":"Small-molecule kinase inhibitors: an analysis of FDA-approved drugs","volume":"21","author":"Wu","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"33","key":"10.1016\/j.bcp.2026.118436_b0075","doi-asserted-by":"crossref","first-page":"13764","DOI":"10.1002\/anie.201914525","article-title":"New promise and opportunities for allosteric kinase inhibitors","volume":"59","author":"Lu","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"5","key":"10.1016\/j.bcp.2026.118436_b0080","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1124\/mol.114.095489","article-title":"25 years of small molecular weight kinase inhibitors: potentials and limitations","volume":"87","author":"Fabbro","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118436_b0085","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BST20220940","article-title":"Allosteric regulation and inhibition of protein kinases","volume":"51","author":"Mingione","year":"2023","journal-title":"Biochem. Soc. Trans."},{"issue":"6513","key":"10.1016\/j.bcp.2026.118436_b0090","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc2754","article-title":"Conformational states dynamically populated by a kinase determine its function","volume":"370","author":"Xie","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bcp.2026.118436_b0095","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.ccell.2024.08.004","article-title":"Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy","volume":"42","author":"Eide","year":"2024","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bcp.2026.118436_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167349","article-title":"Imatinib can act as an allosteric activator of Abl Kinase","volume":"434","author":"Xie","year":"2022","journal-title":"J. Mol. Biol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118436_b0105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.bcp.2026.118436_b0110","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2026.118436_b0115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2026.118436_b0120","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/1471-2407-12-563","article-title":"Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism","volume":"12","author":"Khateb","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2026.118436_b0125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/1471-2407-12-411","article-title":"Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I","volume":"12","author":"Mian","year":"2012","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2026.118436_b0130","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00277-020-04357-z","article-title":"Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)","volume":"100","author":"Mian","year":"2021","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118436_b0135","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1021\/acsmedchemlett.7b00084","article-title":"(19)F-NMR-based dual-site reporter assay for the discovery and distinction of catalytic and allosteric kinase inhibitors","volume":"8","author":"Skora","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.bcp.2026.118436_b0140","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.tips.2020.02.001","article-title":"Combining allosteric and orthosteric drugs to overcome drug resistance","volume":"41","author":"Ni","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2026.118436_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104141","article-title":"Designed dualsteric modulators: a novel route for drug discovery","volume":"29","author":"Li","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"D1","key":"10.1016\/j.bcp.2026.118436_b0150","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: a curated database of somatic variants and clinical data for cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118436_b0155","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1038\/s41467-019-10489-2","article-title":"A pan-cancer analysis of synonymous mutations","volume":"10","author":"Sharma","year":"2019","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bcp.2026.118436_b0160","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1073\/pnas.1907126117","article-title":"Synonymous codon substitutions perturb cotranslational protein folding in vivo and impair cell fitness","volume":"117","author":"Walsh","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.bcp.2026.118436_b0165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/jmcb\/mjy049","article-title":"A single synonymous mutation determines the phosphorylation and stability of the nascent protein","volume":"11","author":"Karakostis","year":"2019","journal-title":"J. Mol. Cell Biol."},{"issue":"18","key":"10.1016\/j.bcp.2026.118436_b0170","doi-asserted-by":"crossref","first-page":"17714","DOI":"10.1021\/acsomega.9b02103","article-title":"Unraveling the role of silent mutation in the omega-subunit of Escherichia coli RNA polymerase: structure transition inhibits transcription","volume":"4","author":"Patel","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.bcp.2026.118436_b0175","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1016\/j.csbj.2025.07.039","article-title":"Improving prediction accuracy in chimeric proteins with windowed multiple sequence alignment","volume":"27","author":"Vedula","year":"2025","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"7","key":"10.1016\/j.bcp.2026.118436_b0180","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1021\/jm101506n","article-title":"Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class","volume":"54","author":"Salah","year":"2011","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2026.118436_b0185","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.seminoncol.2015.09.023","article-title":"MEK1\/2 inhibitors: molecular activity and resistance mechanisms","volume":"42","author":"Wu","year":"2015","journal-title":"Semin. Oncol."},{"issue":"6132","key":"10.1016\/j.bcp.2026.118436_b0190","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bcp.2026.118436_b0195","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"7712","key":"10.1016\/j.bcp.2026.118436_b0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-018-0251-7","article-title":"Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations","volume":"559","author":"Intlekofer","year":"2018","journal-title":"Nature"},{"issue":"7610","key":"10.1016\/j.bcp.2026.118436_b0205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"36","key":"10.1016\/j.bcp.2026.118436_b0210","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107207118","article-title":"Allosteric MEK inhibitors act on BRAF\/MEK complexes to block MEK activation","volume":"118","author":"Gonzalez-Del Pino","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5272","key":"10.1016\/j.bcp.2026.118436_b0215","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.273.5272.239","article-title":"Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP","volume":"273","author":"Choi","year":"1996","journal-title":"Science"},{"issue":"Pt 4","key":"10.1016\/j.bcp.2026.118436_b0220","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1107\/S0907444998014747","article-title":"Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 a resolution","volume":"55","author":"Liang","year":"1999","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"issue":"1","key":"10.1016\/j.bcp.2026.118436_b0225","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"324","key":"10.1016\/j.bcp.2026.118436_b0230","doi-asserted-by":"crossref","first-page":"ra41","DOI":"10.1126\/scisignal.2005050","article-title":"Chloride sensing by WNK1 involves inhibition of autophosphorylation","volume":"7","author":"Piala","year":"2014","journal-title":"Sci. Signal."},{"issue":"5179","key":"10.1016\/j.bcp.2026.118436_b0235","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.8085158","article-title":"Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation","volume":"265","author":"Freed","year":"1994","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2026.118436_b0240","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033746","article-title":"Ras-mediated activation of the Raf family kinases","volume":"9","author":"Terrell","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.118436_b0245","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118436_b0250","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2026.118436_b0255","doi-asserted-by":"crossref","unstructured":"N.P. Shah, R. Bhatia, J.K. Altman, M. Amaya, K.H. Begna, E. Berman, O. Chan, J. Clements, R.H. Collins, P.T. Curtin, D.J. DeAngelo, M. Drazer, L. Maness, L. Metheny, S. Mohan, J.O. Moore, V. Oehler, K. Pratz, I. Pusic, M.G. Rose, W. Shomali, B.D. Smith, M. Styler, M. Talpaz, T.N. Tanaka, S. Tantravahi, J. Thompson, S. Tsai, J. Vaughn, J. Welborn, D.T. Yang, H. Sundar, K. Gregory, Chronic myeloid leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw 22(1) (2024) 43-69.","DOI":"10.6004\/jnccn.2024.0007"},{"issue":"7397","key":"10.1016\/j.bcp.2026.118436_b0260","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118436_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.bcp.2026.118436_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104424","article-title":"Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy","volume":"201","author":"Ruglioni","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"17","key":"10.1016\/j.bcp.2026.118436_b0275","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70055","article-title":"Gilteritinib in FLT3-mutated acute myeloid leukemia: a real-world italian experience","volume":"131","author":"Cairoli","year":"2025","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bcp.2026.118436_b0280","doi-asserted-by":"crossref","first-page":"943","DOI":"10.18632\/oncotarget.27489","article-title":"Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells","volume":"11","author":"Aikawa","year":"2020","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bcp.2026.118436_b0285","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.bcp.2026.118436_b0290","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118436_b0295","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.118436_b0300","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-024-01632-8","article-title":"Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead","volume":"17","author":"Nadiminti","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118436_b0305","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"issue":"7954","key":"10.1016\/j.bcp.2026.118436_b0310","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bcp.2026.118436_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1012302","article-title":"A comprehensive exploration of the druggable conformational space of protein kinases using AI-predicted structures","volume":"20","author":"Herrington","year":"2024","journal-title":"PLoS Comput. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118436_b0320","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1021\/acschembio.2c00868","article-title":"Capturing differences in the regulation of LRRK2 dynamics and conformational states by small molecule kinase inhibitors","volume":"18","author":"Weng","year":"2023","journal-title":"ACS Chem. Biol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118436_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104466","article-title":"Recent advances in computational strategies for allosteric site prediction: machine learning, molecular dynamics, and network-based approaches","volume":"30","author":"Huang","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2026.118436_b0330","doi-asserted-by":"crossref","unstructured":"X. Huang, K. Wang, J. Han, X. Chen, Z. Wang, T. Wu, B. Yu, F. Zhao, X. Wang, H. Li, Z. Xie, X. Zhu, W. Zhong, X. Ren, Cryo-EM structures reveal two allosteric inhibition modes of PI3Kalpha(H1047R) involving a re-shaping of the activation loop, Structure 32(7) (2024) 907-917 e7.","DOI":"10.1016\/j.str.2024.03.007"},{"issue":"12","key":"10.1016\/j.bcp.2026.118436_b0335","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/leu.2017.264","article-title":"Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib","volume":"31","author":"Qiang","year":"2017","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.bcp.2026.118436_b0340","doi-asserted-by":"crossref","first-page":"13423","DOI":"10.18632\/oncotarget.24393","article-title":"The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro","volume":"9","author":"Eadie","year":"2018","journal-title":"Oncotarget"},{"issue":"252","key":"10.1016\/j.bcp.2026.118436_b0345","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118436_b0350","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2009.017178","article-title":"Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4\/CXCL12 axis","volume":"95","author":"Vianello","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bcp.2026.118436_b0355","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","article-title":"Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results","volume":"37","author":"Mauro","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bcp.2026.118436_b0360","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/cts.13285","article-title":"Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents","volume":"15","author":"Hoch","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"14","key":"10.1016\/j.bcp.2026.118436_b0365","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118436_b0370","first-page":"1477","article-title":"Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases","volume":"11","author":"Rodig","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"8016","key":"10.1016\/j.bcp.2026.118436_b0375","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118436_b0380","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-026-01411-9","article-title":"Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies","author":"Rudolph","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.bcp.2026.118436_b0385","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: a major contributor to minimal residual disease","volume":"9","author":"Meads","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"17","key":"10.1016\/j.bcp.2026.118436_b0390","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1182\/blood.2025028539","article-title":"Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1","volume":"146","author":"Shi","year":"2025","journal-title":"Blood"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:02:03Z","timestamp":1789110123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226007756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":78,"alternative-id":["S0006295226007756"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118436","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118436"}}